{
    "xml": "<topic id=\"PHP764\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/enoximone\" basename=\"enoximone\" title=\"ENOXIMONE\">\n<title>ENOXIMONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1038\" namespace=\"/interactions/list-of-drug-interactions/phosphodiesterase-type-3-inhibitors/enoximone\">Enoximone</xref>\n</p>\n<data name=\"vtmid\">320067009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_252425805\" title=\"Phosphodiesterase type-3 inhibitors\">Phosphodiesterase type-3 inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP71027\" outputclass=\"drugAction\" rev=\"1.5\" parent=\"/drugs/enoximone\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70944\" outputclass=\"indicationsAndDose\" rev=\"1.37\" parent=\"/drugs/enoximone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Congestive heart failure where cardiac output reduced and filling pressures increased</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By slow intravenous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 0.5&#8211;1&#8239;mg/kg, rate not exceeding 12.5&#8239;mg/minute, then 500&#8239;micrograms/kg every 30&#8239;minutes (max. per dose 3&#8239;mg/kg) until a satisfactory response is achieved or maximum dose reached; maintenance up to 3&#8239;mg/kg every 3&#8211;6&#8239;hours as required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 90&#8239;micrograms/kg/minute, dose to be given over 10&#8211;30 minutes, followed by 5&#8211;20&#8239;micrograms/kg/minute, dose to be given as either a continuous or intermittent infusion; maximum 24&#8239;mg/kg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71079\" outputclass=\"cautions\" rev=\"1.5\" parent=\"/drugs/enoximone\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70919\" outputclass=\"interactions\" rev=\"1.5\" parent=\"/drugs/enoximone\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (phosphodiesterase type-3 inhibitors).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70849\" outputclass=\"sideEffects\" rev=\"1.5\" parent=\"/drugs/enoximone\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Chills</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">ectopic beats</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oliguria</ph>; <ph outputclass=\"sideEffect\">supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias)</ph>; <ph outputclass=\"sideEffect\">upper and lower limb pain</ph>; <ph outputclass=\"sideEffect\">urinary retention</ph>; <ph outputclass=\"sideEffect\">ventricular tachycardia (more likely in patients with pre-existing arrhythmias)</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70910\" outputclass=\"pregnancy\" parent=\"/drugs/enoximone\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises use only if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71099\" outputclass=\"breastFeeding\" parent=\"/drugs/enoximone\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70991\" outputclass=\"hepaticImpairment\" parent=\"/drugs/enoximone\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70883\" outputclass=\"renalImpairment\" parent=\"/drugs/enoximone\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Consider dose reduction.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP70790\" outputclass=\"monitoringRequirements\" parent=\"/drugs/enoximone\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71132\" outputclass=\"directionsForAdministration\" rev=\"1.9\" parent=\"/drugs/enoximone\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Incompatible with glucose solutions.</p>\n<p>Use only plastic containers or syringes; crystal formation if glass used.</p>\n<p>Avoid extravasation.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous infusion</i> (<i>Perfan</i>\n<tm tmtype=\"reg\"/>), give continuously or intermittently in Sodium chloride 0.9% or Water for injections; dilute to a concentration of 2.5&#8239;mg/mL.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP61518\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.12\" parent=\"/drugs/enoximone\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP764-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/enoximone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76055\" title=\"Solution for injection\" namespace=\"/drugs/enoximone/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1038\" namespace=\"/interactions/list-of-drug-interactions/phosphodiesterase-type-3-inhibitors/enoximone\" title=\"Enoximone\" count=\"1\" rel=\"link\">Enoximone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76055\" namespace=\"/drugs/enoximone/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP764",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/enoximone",
    "basename": "enoximone",
    "title": "ENOXIMONE",
    "interactants": [
        {
            "id": "bnf_int_1038",
            "label": "Enoximone"
        }
    ],
    "vtmid": "320067009",
    "drugClassification": [
        "Phosphodiesterase type-3 inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.",
                "html": "<p>Enoximone is a phosphodiesterase type-3 inhibitor that exerts most effect on the myocardium; it has positive inotropic properties and vasodilator activity.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Congestive heart failure where cardiac output reduced and filling pressures increased",
                        "html": "Congestive heart failure where cardiac output reduced and filling pressures increased"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 0.5&#8211;1 mg/kg, rate not exceeding 12.5 mg/minute, then 500 micrograms/kg every 30 minutes (max. per dose 3 mg/kg) until a satisfactory response is achieved or maximum dose reached; maintenance up to 3 mg/kg every 3&#8211;6 hours as required.",
                        "html": "<p>Initially 0.5&#8211;1&#8239;mg/kg, rate not exceeding 12.5&#8239;mg/minute, then 500&#8239;micrograms/kg every 30&#8239;minutes (max. per dose 3&#8239;mg/kg) until a satisfactory response is achieved or maximum dose reached; maintenance up to 3&#8239;mg/kg every 3&#8211;6&#8239;hours as required.</p>"
                    },
                    {
                        "textContent": "Initially 90 micrograms/kg/minute, dose to be given over 10&#8211;30 minutes, followed by 5&#8211;20 micrograms/kg/minute, dose to be given as either a continuous or intermittent infusion; maximum 24 mg/kg per day.",
                        "html": "<p>Initially 90&#8239;micrograms/kg/minute, dose to be given over 10&#8211;30 minutes, followed by 5&#8211;20&#8239;micrograms/kg/minute, dose to be given as either a continuous or intermittent infusion; maximum 24&#8239;mg/kg per day.</p>"
                    }
                ]
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction",
                "html": "Heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive valvular disease or other outlet obstruction"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (phosphodiesterase type-3 inhibitors).",
                "html": "<p>Appendix 1 (phosphodiesterase type-3 inhibitors).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Chills",
                        "html": "Chills",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ectopic beats",
                        "html": "ectopic beats",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oliguria",
                        "html": "oliguria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias)",
                        "html": "supraventricular arrhythmias (more likely in patients with pre-existing arrhythmias)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "upper and lower limb pain",
                        "html": "upper and lower limb pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urinary retention",
                        "html": "urinary retention",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ventricular tachycardia (more likely in patients with pre-existing arrhythmias)",
                        "html": "ventricular tachycardia (more likely in patients with pre-existing arrhythmias)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises use only if potential benefit outweighs risk.",
                "html": "<p>Manufacturer advises use only if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;no information available.",
                "html": "<p>Manufacturer advises caution&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required.",
                "html": "<p>Dose reduction may be required.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Consider dose reduction.",
                "html": "<p>Consider dose reduction.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.",
                "html": "<p>Monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count and hepatic enzymes.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Incompatible with glucose solutions.\n\nUse only plastic containers or syringes; crystal formation if glass used.\n\nAvoid extravasation.",
                "html": "<p>Incompatible with glucose solutions.</p><p>Use only plastic containers or syringes; crystal formation if glass used.</p><p>Avoid extravasation.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion (Perfan ), give continuously or intermittently in Sodium chloride 0.9% or Water for injections; dilute to a concentration of 2.5 mg/mL.",
                "html": "<p>For <i>intravenous infusion</i> (<i>Perfan</i>\n<tm tmtype=\"reg\"/>), give continuously or intermittently in Sodium chloride 0.9% or Water for injections; dilute to a concentration of 2.5&#8239;mg/mL.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.",
                "html": "<p>Sustained haemodynamic benefit has been observed after administration of phosphodiesterase type-3 inhibitors, but there is no evidence of any beneficial effect on survival.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76055",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1038",
                "label": "Enoximone",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76055",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}